Genetic Technologies (ASX:GTG) FCF Margin %: 0.00% (As of Jun. 2024)


What is Genetic Technologies FCF Margin %?

Genetic Technologies ASX:GTG FCF Margin % is 0.00% as of Jun. 2024.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Genetic Technologies's Free Cash Flow for the three months ended in Jun. 2024 was A$-3.11 Mil. Genetic Technologies's Revenue for the three months ended in Jun. 2024 was A$0.00 Mil. Therefore, Genetic Technologies's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Genetic Technologies's current FCF Yield % is 0.00%.

The historical rank and industry rank for Genetic Technologies's FCF Margin % or its related term are showing as below:

ASX:GTG' s FCF Margin % Range Over the Past 10 Years
Min: -82.73   Med: 0   Max: 0
Current: -82.73

ASX:GTG's FCF Margin % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -1.845 vs ASX:GTG: -82.73

Genetic Technologies FCF Margin % Related Terms

Genetic Technologies FCF Margin % Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies FCF Margin % Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -57,500.00 -5,822.31 -84.71 -112.15 -126.71

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:GTG vs LDDD, NOTV, ATLN: FCF Margin % Comparison

For the Diagnostics & Research subindustry, Genetic Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies FCF Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's FCF Margin % falls into.


Genetic Technologies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Genetic Technologies's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Jun. 2024 )/Revenue (A: Jun. 2024 )
=-9.712/7.665
=-126.71 %

Genetic Technologies's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-3.11/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Genetic Technologies (ASX:GTG) has a FCF Margin % of 0.00% as of Jun. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' FCF Margin % too high?
Genetic Technologies' current FCF Margin % is 0.00%.
How does Genetic Technologies' FCF Margin % compare to LDDD and NOTV?
Genetic Technologies' FCF Margin % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current FCF Margin % is 0.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.